<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="347757">
  <stage>Registered</stage>
  <submitdate>18/01/2012</submitdate>
  <approvaldate>23/01/2012</approvaldate>
  <actrnumber>ACTRN12612000104853</actrnumber>
  <trial_identification>
    <studytitle>Total and free serum Ropivacaine Concentrations for patients receiving Continuous Transversus Abdominis plane block for Postoperative analgesia after abdominal surgery:  Pilot Study</studytitle>
    <scientifictitle>Total and free serum Ropivacaine Concentrations for patients receiving Continuous Transversus Abdominis plane block for Postoperative analgesia after abdominal surgery:  Pilot Study</scientifictitle>
    <utrn />
    <trialacronym>ROP- CON study</trialacronym>
    <secondaryid>none</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Local anaestetic concentration after a bolus followed by continuous infusion in TAP block</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Anaesthetics</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients having mid line incision will have  TAP block  catheter towards the end of surgery. They will recieve 20 mls of 0.5% ropivacaine Bilateral (both sides) followed by continous infusion of 10mls/hr of 0.2% ropivacaine for 48hrs which will be started 30mins post 2nd bolus.</interventions>
    <comparator>none</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Total and free ropivacaine concentration will be analysed using High Performance Liquid Chromatograph(HPLC).</outcome>
      <timepoint>predose, 15 mins post 2nd bolus, 30 mins, 45 mins, 60 mins, 2hr, 4hr, 8hr, 12hr,24 hr, 48 hr</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Serial ECG's will be done to monitor any arrhythmia &amp; to measure QTc interval as a prolonged QT interval is a biomarker for ventricular tachyarrhythmias.</outcome>
      <timepoint>pre op, 6hrs post 2nd bolus, 12hrs, 24 hrs, 48hrs</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>patients will be observed for sign &amp; symptoms of Local anesthetic toxicity in terms of: BP, HR &amp; rhythum, peri oral / tongue numbness, any visual changes, muscle twitching, convulsions</outcome>
      <timepoint>15mins( 2nd bolus), 30mins, 45 mins, 60 mins, 2 hrs, 4hr, 8 hr, 12hr, 24hr &amp; 48hr</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Elective/Emergency abdominal surgery
	Between 18 and 80 years of age
	ASA less than 4
	Adequate English language skills</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1 Allergy to local anaesthetic
2 Pt refusal 
3 ASA score &gt; 4 (i.e 4,5)
4 Pregnancy
5 On regular opioid medication or any other medication for 
   chronic pain management.
6 Mental handicap or psychiatric condition precluding adequat
   communication.
7 Patients taking ciprofloxacin &amp; fluvoxamine (affects
    the metabolism of LA)
8 Qt c interval &gt; 0.45 sec in males and &gt; 0.47 sec in females
9 Drugs affecting Qtc interval e.g. Haloperidol, Amiodarone,
   Sotaol</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>5/10/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>15</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Sarika Kumar</primarysponsorname>
    <primarysponsoraddress>The Queen Elizabeth Hospital
28 Woodville Road
Woodville South
SA
5011</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Dr Vasanth Rao</sponsorname>
      <sponsoraddress>The Queen Elizabeth Hospital
28 Woodville Road
Woodville South
SA
5011</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Dr Richard Watts</sponsorname>
      <sponsoraddress>The Queen Elizabeth Hospital
28 Woodville Road
Woodville South
SA
5011</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a pilot study looking into safety of giving bolus of ropivacaine followed by continous infusion for 48 hrs in Transversus Abdominis Plane Block. Safety of this regime will be established by serial blood samples to analyse toal &amp; free ropivacaine concentration , Serail ECG 's looking into QTc interval &amp; patient will be observed for sign &amp; symptoms of Local anaesthetic toxicity</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Humen Research Ethics Committee</ethicname>
      <ethicaddress>The Queen Elizabeth Hospital 
Ethics DX 465101
Ground Floor, Basil Hetzel Institute
28 Woodville Road
WOODVILLE SOUTH  SA  5011</ethicaddress>
      <ethicapprovaldate>24/09/2011</ethicapprovaldate>
      <hrec>2011063</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Vasanth Rao</name>
      <address>28 Woodville Road,
Woodville South, SA 5011</address>
      <phone>+61882226000</phone>
      <fax />
      <email>drvasanthrao@yahoo.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Sarika  Kumar</name>
      <address>28 Woodville Road,
Woodville South, SA 5011</address>
      <phone>+61421916106</phone>
      <fax />
      <email>libransarika@yahoo.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Sarika Kumar</name>
      <address>28 Woodville Road,
Woodville South, SA 5011</address>
      <phone>+61421916106</phone>
      <fax />
      <email>libransarika@yahoo.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>